The PennZone

  • Home
  • Health
  • Non-profit
  • Business
  • Technology
  • Services
  • Construction
  • Sports
  • Books

Olympus Acquires Veran Medical Technologies, Inc.
The PennZone/10102444

Trending...
  • Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.

Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.

More on The PennZone
  • HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Guests Can Save 25 Percent Off Last Minute Bookings at KeysCaribbean's Village at Hawks Cay Villas
  • Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry

"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."

The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.

As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.

More on The PennZone
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
  • Together We Dance Foundation Announces Transformational Support from NAC Have a Heart Foundation
  • Harry Hayman Celebrates Years of WHYY Coverage, Partnership & Shared Commitment to Philadelphia
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Stockwell Elastomerics expands micro molding capabilities

For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."

(available at: https://www.olympus-global.com/news/ir/2020/)

1 WHO data:  https://www.who.int/news-room/fact-sheets/detail/cancer

About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

SOURCE Olympus

Related Links

http://www.olympus.com/
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Teresa James & The Rhythm Tramps announce their new album and debut on MoMojo Records, 'Bad at Being Good'
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Beycome Closes $2.5M Seed Round Led by InsurTech Fund
  • VIP Vacations Invited to Travel Weekly's Annual Readers Choice Awards
  • Tru by Hilton Columbia South Opens to Guests
  • Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
  • "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Women's Everyday Safety Is Changing - The Blue Luna Shows How
  • Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
  • Harry Hayman IV & Gemini Consultants Announce Holiday Toys‑for‑Tots Giveaway with Retired Sixers
  • 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
  • The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
  • AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
  • TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
  • Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
  • Ezra Wohlgelernter Installed Philadelphia Bar Association Chancellor
  • Power Couple Launches "Happy Habits Events" After Best of Philly Win, Pandemic Loss, and Setbacks
  • Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
  • Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club

Popular on PennZone

  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 143
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 123
  • AI, Fintech, and Cybersecurity Divisions Ignite High-Margin Growth: IQSTEL, Inc. (N A S D A Q: IQST)
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth

Similar on PennZone

  • HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
  • Women's Everyday Safety Is Changing - The Blue Luna Shows How
  • AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
  • Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us